Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Authors
Type
Published Article
Journal
HIV clinical trials
Publication Date
Volume
14
Issue
3
Pages
81–91
Identifiers
DOI: 10.1310/hct1403-81
PMID: 23835510
Source
Medline
License
Unknown

Abstract

The pooled ECHO and THRIVE studies demonstrated noninferiority of RPV+FTC/TDF in achieving virologic response with safety and tolerability advantages over EFV+FTC/TDF through 96 weeks. Higher rates of virologic failure in the RPV+FTC/TDF group were balanced with higher rates of discontinuations due to adverse events in the EFV+FTC/TDF group.

Statistics

Seen <100 times